"Conclusions: These studies suggest that mTNBC pts dosed with leronlimab had high clinical benefit, i.e. longer PFS & OS with few TEAEs, and leronlimab resulted in a drop in circulating TACs in the majority of pts correlating with early therapy response."

I'm just in shock that this isn't the mTNBC news of the day at LEAST. This is so huge.

Patients need to learn about this ASAP.